Markets:

Overview

News

Currencies

International

Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ:RETA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 Next >

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shareholder Notice: Investigation over Potential Wrongdoing ↗

October 04, 2023

San Diego, CA -- (SBWIRE) -- 10/04/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Reata Pharmaceuticals, Inc.

Via SBWire

Biogen Completes Acquisition of Reata Pharmaceuticals

September 26, 2023

From Biogen Inc.

Via GlobeNewswire

Reata Pharmaceuticals Inc. (NASDAQ: RETA) Climbs to New 52-Week High

September 21, 2023

Via Investor Brand Network

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

September 21, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 7/17

July 17, 2023

Via Investor Brand Network

Reata Pharmaceuticals Inc. (NASDAQ: RETA) is a Stock Spotlight on 5/5

May 05, 2023

Via Investor Brand Network

REATA PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

August 28, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Earthstone Energy, Inc. (NYSE - ESTE), Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 21, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 17, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)

August 08, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

August 07, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

REATA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Reata Pharmaceuticals, Inc. - RETA

August 02, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Talaris Therapeutics, Inc. (Nasdaq - TALS), Inpixon® (Nasdaq - INPX)

August 01, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Reata Pharmaceuticals, Inc. (Nasdaq – RETA), Talaris Therapeutics, Inc. (Nasdaq – TALS), Inpixon® (Nasdaq – INPX), Amedisys, Inc. (Nasdaq – AMED)

July 28, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®

July 28, 2023

Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a

Via Spotlight Growth

RETA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Reata Pharmaceuticals, Inc. Is Fair to Shareholders

July 28, 2023

From Halper Sadeh LLC

Via Business Wire

Biogen to Acquire Reata Pharmaceuticals

July 28, 2023

From Biogen Inc.

Via GlobeNewswire

Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia

June 27, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating Reata, DLocal, Comerica, and Advance Auto Parts and Encourages Investors to Contact the Firm

June 19, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement

June 15, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

June 13, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating Reata, Comerica, and DZS and Encourages Investors to Contact the Firm

June 09, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

NASDAQ:RETA Investor Alert: Investigation over Possible Securities Laws Violations by Reata Pharmaceuticals, Inc. ↗

June 07, 2023

San Diego, CA -- (SBWIRE) -- 06/07/2023 -- Reata Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

June 06, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm

June 04, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm

May 26, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

May 10, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023

May 02, 2023

From Reata Pharmaceuticals, Inc.

Via Business Wire

REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA

March 31, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

The Stock That Tripled in a Day...And May Not Be Done

March 07, 2023

Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios?

Via MarketBeat

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.